Table 3. Overview of candidate interventions from 265 COVID-19 clinical trials.
| Intervention Categories | Intervention Subcategories | No (%) (n = 265) |
|---|---|---|
| Anti-malarial drugs | 43 (16.2) | |
| Chloroquine phosphate | 30 | |
| Hydroxychloroquine | 7 | |
| Phosphoric chloroquine | 4 | |
| Chloroquine | 2 | |
| Anti-viral drugs | 29 (10.9) | |
| Ritonavir plus lopinavir | 8 | |
| Recombinant interferon | 4 | |
| Favipiravir | 4 | |
| Azzedine | 3 | |
| Baloxavir marboxil | 2 | |
| Darunavir | 2 | |
| Ganovo | 2 | |
| ASC09/ritonavir | 1 | |
| Arbidol hydrochloride | 1 | |
| Carrimycin | 1 | |
| Triazavirin | 1 | |
| Stem cells | 16 (6.0) | |
| Mesenchymal stem cells | 9 | |
| Umbilical cord mesenchymal stem cell-conditioned medium | 1 | |
| Umbilical cord blood mononuclear cells | 1 | |
| Menstrual blood-derived stem cells | 1 | |
| Human menstrual blood-derived stem cells | 1 | |
| NK cells and mesenchymal stem cells | 1 | |
| Umbilical cord blood plasma | 1 | |
| Cord blood mesenchymal stem cells | 1 | |
| Immunomodulators | 13 (4.9) | |
| Convalescent plasma | 11 | |
| CMAB806 (IL-6) | 1 | |
| NLRP Inflammasome inhibitor (Tranilast) | 1 | |
| Monoclonal antibodies | 6 (2.3) | |
| Tocilizumab | 2 | |
| Adalimumab | 1 | |
| Ixekizumab | 1 | |
| Camrelizumab | 1 | |
| PD-1 | 1 | |
| Corticosteroid | Methylprednisolone | 4 (1.5) |
| Vaccine | 4 (1.5) | |
| Vaccine (adenoviral vector) | 2 | |
| Vaccine (vero cells) | 1 | |
| DC vaccine | 1 |